Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 5, 2014, Pages 735-742

  Zhou, Feng ^a   Tao, Guohua ^a   Chen, Xiang ^a   Xie, Wei ^a   Liu, Manhua ^a   Cao, Xingjian ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

5 AZA treatment; clinical outcome; gene methylation; OPCML; ovarian cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; ENZYME INHIBITOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; OPCML PROTEIN, HUMAN; RNA;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; FEMALE; FLUORESCENCE; GENE EXPRESSION; GENETIC ASSOCIATION; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; ONCOGENE; OPIOID BINDING PROTEIN CELL ADHESION MOLECULE LIKE GENE; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; AGE; AGED; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGE FACTORS; AGED; AZACITIDINE; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; GPI-LINKED PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SEQUENCE ANALYSIS, DNA;

EID: 84898950744     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0736     Document Type: Article

References (41)

1. Shigetomi H, Higashiura Y, Kajihara H, Kobayashi H. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review). Oncol Rep 2012;28:395-408.
2. Mould T. An overview of current diagnosis and treatment in ovarian cancer. Int J Gynecol Cancer 2012;22:S2-4.
3. Bast RC Jr. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol 2011;22:viii5-15.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
5. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-7. (Pubitemid 37373908)
6. Poumpouridou N, Kroupis C. Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. Clin Chem Lab Med 2011;23:423-34.
7. Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, et al. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phospho-peptide-binding pocket: a multi-modal approach. Eur J Hum Genet 2008;16:820-32. (Pubitemid 351865680)
8. Bird A. Perceptions of epigenetics. Nature 2007;447:396-8. (Pubitemid 46816744)
9. Novak K. Epigenetics changes in cancer cells. Med Gen Med 2004;6:17.
10. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8:286-98. (Pubitemid 46439286)
11. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54. (Pubitemid 37448928)
12. Bell J. Predicting disease using genomics. Nature 2004;429:453-6. (Pubitemid 38715139)
13. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
14. Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004;191:1552-72. (Pubitemid 39491180)
15. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemore-sistance. Oncogene 2007;26:4969-78. (Pubitemid 47172647)
16. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003;34:337-43. (Pubitemid 36792869)
17. Mei FC, Young TW, Liu J, Cheng X. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB J 2006;20:497-9. (Pubitemid 46671228)
18. Ntougkos E, Rush R, Scott D, Frankenberg T, Gabra H, Smyth JF, et al. The IgLON family in epithelial ovarian cancer: expression profiles and clinicopathologic correlates. Clin Cancer Res 2005;11:5764-8. (Pubitemid 41170301)
19. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005;65:8961-7. (Pubitemid 41377387)
20. Czekierdowski A, Czekierdowska S, Szymanski M, Wielgos M, Kaminski P, Kotarski J. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer. Neuro Endocrinol Lett 2006;27:609-13. (Pubitemid 46050018)
21. Chen H, Ye F, Zhang J, Lu W, Cheng Q, Xie X. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma. Eur J Gynaecol Oncol 2007;28:464-7.
22. Zhou F, Cao X, Liu M, Wang Y, Tao G. A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection. Clin Lab 2011;57:421-4.
23. Duarte-Pereira S, Paiva F, Costa VL, Ramalho-Carvalho J, Savva-Bordalo J, Rodrigues A, et al. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur J Cancer 2011;47:1106-14.
24. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003;9:827-36. (Pubitemid 36182621)
25. Melichar B, Kroupis C. Cancer epigenomics: moving slowly, but at a steady pace from laboratory bench to clinical practice. Clin Chem Lab Med 2012;50:1699-701.
26. Heichman KA, Warren JD. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 2012;50:1707-21.
27. Toraño EG, Petrus S, Fernandez AF, Fraga MF. Global DNA hypomethylation in cancer: review of validated methods and clinical significance. Clin Chem Lab Med 2012;50:1733-42.
28. Borley J, Wilhelm-Benartzi C, Brown R, Ghaem-Maghami S. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer 2012;107:1069-74.
29. Gui T, Shen K. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol 2012;36:490-6.
30. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 2012; 31:14.
31. Ng JS, Low JJ, Ilancheran A. Epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2012;26:337-45.
32. Diaz-Padilla I, Razak AR, Minig L, Bernardini MQ, Maria Del Campo J. Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls. Clin Transl Oncol 2012;14:15-20.
33. Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, et al. HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem 2011;55:1-20.
34. Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Fürst S, Mayr D, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011;49:2081-8.
35. Reed JE, Dunn JR, du Plessis DG, Shaw EJ, Reeves P, Gee AL, et al. Expression of cellular adhesion molecule 'OPCML' is down-regulated in gliomas and other brain tumours. Neuropathol Appl Neurobiol 2007;33:77-85. (Pubitemid 46090312)
36. Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, et al. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 2007;6:70.
37. Sriraksa R, Zeller C, El-Bahrawy MA, Dai W, Daduang J, Jearanaikoon P, et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer 2011;104:1313-8.
38. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One 2008;3:e2990.
39. Xu XC. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett 2007;253:14-24.
40. McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, et al. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov 2012;2:156-71.
41. Wu SY, Sood AK. New roles opined for OPCML. Cancer Discov 2012;2:115-6.